These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

646 related items for PubMed ID: 30852425

  • 1. Successes and challenges for preventing measles, mumps and rubella by vaccination.
    Bankamp B, Hickman C, Icenogle JP, Rota PA.
    Curr Opin Virol; 2019 Feb; 34():110-116. PubMed ID: 30852425
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
    McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS, Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 2013 Jun 14; 62(RR-04):1-34. PubMed ID: 23760231
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antibodies to measles, mumps, and rubella virus in Thai children after two-dose vaccination at 9 months and 2.5 years: A longitudinal study.
    Wanlapakorn N, Puenpa J, Thongmee T, Srimuan D, Thatsanathorn T, Vongpunsawad S, Poovorawan Y.
    Vaccine; 2020 May 19; 38(24):4016-4023. PubMed ID: 32331806
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. MMR vaccination and disease elimination: the Finnish experience.
    Davidkin I, Kontio M, Paunio M, Peltola H.
    Expert Rev Vaccines; 2010 Sep 19; 9(9):1045-53. PubMed ID: 20822347
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR, Choe YJ, Go UY, Kim YI, Lee JK.
    Vaccine; 2013 May 31; 31(24):2661-6. PubMed ID: 23602654
    [Abstract] [Full Text] [Related]

  • 19. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P.
    Pediatr Infect Dis J; 2008 Aug 31; 27(8):724-30. PubMed ID: 18600190
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.